Therapeutic Area: Oncology

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma

Bajor et al.
Cancer Immunology Research
Papers
November 2014
Authors and Affiliates
Bajor DL1, Xu X2, Torigian DA3, Mick R4, Garcia LR5, Richman LP5, Desmarais C6, Nathanson KL7, Schuchter LM1, Kalos M2, Vonderheide RH8 1Abramson Cancer Center, University of Pennsylvania, Philadelphia. Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 2Abramson Cancer Center, University of Pennsylvania, Philadelphia. Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 3Abramson Cancer Center, University of Pennsylvania, Philadelphia. Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 4Abramson Cancer Center, University of Pennsylvania, Philadelphia. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 5Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, 6Adaptive Biotechnologies, Seattle, Washington, 7Abramson Cancer Center, University of Pennsylvania, Philadelphia. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 8Abramson Cancer Center, University of Pennsylvania, Philadelphia. Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. rhv@exchange.upenn.edu.

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh et al.
Nature
Papers
November 2014
immuneAccess
Authors and Affiliates
Tumeh PC1, Harview CL2, Yearley JH3, Shintaku IP2, Taylor EJ2, Robert L2, Chmielowski B1, Spasic M2, Henry G2, Ciobanu V2, West AN2, Carmona M2, Kivork C2, Seja E2, Cherry G2, Gutierrez AJ2, Grogan TR2, Mateus C4, Tomasic G4, Glaspy JA1, Emerson RO5, Robins H6, Pierce RH3, Elashoff DA1, Robert C4, Ribas A1. 1University of California Los Angeles (UCLA), Los Angeles, California 90095, USA [2] Jonsson Comprehensive Cancer Center, Los Angeles, California 90095, USA. 2University of California Los Angeles (UCLA), Los Angeles, California 90095, USA. 3Merck &Co, Palo Alto, California 94304, USA. 4Gustave Roussy and INSERM U981, Villejuif, Paris Sud, France. 5Adaptive Biotechnologies, Seattle, Washington 98102, USA. 6Adaptive Biotechnologies, Seattle, Washington 98102, USA [2] Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.

The Evolution of Thymic Lymphomas in P53 Knockout Mice

Dudgeon et al.
Genes & Development
Papers
October 2014
immuneAccess
Authors and Affiliates
Dudgeon C1,6, Chan C1,2,6, Kang W1, Sun Y1, Emerson R3, Robins H3,4, Levine AJ1,5 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ1; Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ2; Biomarker Discovery, Adaptive Biotechnologies, Seattle, WA3; Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA4; Simons Center for Systems Biology, School of Natural Sciences, Institute for Advanced Study, Princeton, NJ5

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells

Pollack et al.
Journal for ImmunoTherapy of Cancer
Papers
October 2014
Authors and Affiliates
Seth M Pollack, Robin L Jones, Erik A Farrar, Ivy P Lai, Sylvia M Lee, Jianhong Cao, Venu G Pillarisetty, Benjamin L Hoch, Ashley Gullett, Marie Bleakley, Ernest U Conrad, Janet F Eary, Kendall C Shibuya, Edus H Warren, Jason N Carstens, Shelly Heimfeld, Stanley R Riddell and Cassian Yee. Clinical Research Division, D3-100 Fred Hutchinson Cancer Research Center, 1100 Fairview Ave, Seattle, WA 98109 USA Department of Medicine, University of Washington, Seattle, WA USA Department of Surgery, University of Washington, Seattle, WA USA Department of Pathology, University of Washington, Seattle, WA USA Department of Pediatrics, University of Washington, Seattle, WA USA Department of Orthopedics, University of Washington, Seattle, WA USA Department of Radiology, University of Alabama, Birmingham, AL USA Institute for Advanced Study, Technical University of Munich, Munich, Germany Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, 7455 Fannin St, Unit 904, Houston, TX 77054 USA

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

Robert et al.
Clinical Cancer Research
Papers
May 2014
immuneAccess
Authors and Affiliates
Lidia Robert,1 Jennifer Tsoi,2 Xiaoyan Wang,1,3 Ryan Emerson,7,8 Blanca Homet,1,9 Thinle Chodon,1 Stephen Mok,1,2Rong Rong Huang,4 Alistair J. Cochran,4 Begonya Comin-Anduix,5,6 Richard C. Koya,4,6 Thomas G. Graeber,2,6 Harlan Robins,7,8 and Antoni Ribas1,2,4,6 1Department of Medicine (Division of Hematology-Oncology), University of California Los Angeles (UCLA), 2Department of Molecular and Medical Pharmacology, University of California Los Angeles (UCLA), 3Department of Medicine (Statistics core), University of California Los Angeles (UCLA), 4Department of Pathology and Laboratory Medicine, University of California Los Angeles (UCLA), 5Department of Surgery (Division of Surgical-Oncology), University of California Los Angeles (UCLA), 6Jonsson Comprehensive Cancer Center (JCCC), University of California Los Angeles (UCLA), 7Fred Hutchinson Cancer Research Center, Seattle, WA, 8Adaptive Biotechnologies, Seattle, WA, 9Instituto de Salud Carlos III, Madrid, Spain

Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I

Chapuis et al.
Cancer Immunology Research
Papers
January 2014
Authors and Affiliates
Chapuis AG1, Afanasiev OK2, Iyer JG3, Paulson KG2, Parvathaneni U4, Hwang JH5, Lai I1, Roberts IM1, Sloan HL1, Bhatia S6, Shibuya KC1, Gooley T1, Desmarais C7, Koelle DM8, Yee C1, Nghiem P2. 1Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA, 2Department of Pathology, University of Washington, Seattle, WA, USA ; Department of Medicine (Dermatology), University of Washington, Seattle, WA, USA, 3Department of Medicine (Dermatology), University of Washington, Seattle, WA, USA, 4Division of Radiation Oncology, UWMC, Seattle, WA, USA, 5Division of Gastroenterology, UWMC, Seattle, WA, USA, 6Department of Medicine (Medical Oncology), University of Washington, Seattle, WA, USA, 7Adaptive Biotechnologies, Seattle, WA, USA, 8Department of Medicine (Dermatology), University of Washington, Seattle, WA, USA ; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA ; Department of Global Health, University of Washington, Seattle, WA, USA ; Vaccine and Infectious Disease Division, FHCRC, Seattle, WA, USA ; Benaroya Research Institute, Seattle, WA, USA.

Tumor-Associated Immune Parameters for Personalized Patient Care

Pagès
Papers
Science Translational Medicine
December 2013
Authors and Affiliates
Franck Pagès Laboratory of Immunology, Immunomonitoring Platform, Georges Pompidou European Hospital, AP-HP, Paris Descartes University, Laboratory of Integrative Cancer Immunology, INSERM U872, Cordeliers Research Center, Paris, France.